Boston, MA 07/26/2013 (wallstreetpr) – On behalf of the security purchasers of Sequenom Inc (NASDAQ:SQNM), the potential claims is being investigated by Howard G. Smith law offices. These claims are concerning the possibilities of violations of the laws of federal securities. These investigations has its’ focus on the certain statements which are concerning the company’s operations and financial performances were issued by Sequenom Inc between the period of May 9th and July 24th of this year.
More recently, Sequenom Inc has reported its second quarter financial results of the year 2013. In this report, the company disclosed that out of the total revenues, the diagnostic revenues accounted for 70% during this quarter while this type of revenue accounted for 76% of the total revenues during the first quarter of this year.
As like many other companies in the diagnostic market, Sequenom Inc also has experienced a delay in payments from the clients. This is due to the changes in the coding of molecular diagnostics which were adopted by CMS and Medicaid including the third party payers. Many of the payers started requesting additional information to process the claims for services.
Followed by this announcement, the stock of Sequenom Inc fell during the intra-day trading during the last trading session. The stock was observed to have fallen as high as 30% when compared to the closing price previous day’s trading session. The last trading session was opened at $ 3.07 and the mid-day range of trade was remaining between the values of $ 3.00 and $ 3.42 and the value of most recent trade was $ 3.27. As told earlier, there was a negative performance of -30.49% observed. There was a gain of 27.71 million shares in the trading volume while the average trading volume of the company’s stock was remaining as 2.48 million shares. The 52-week trading range of the stock was lying between $2.65 and $5.36.
